North America Test Strips Market size surpassed USD 5.4 billion in 2020 and is anticipated to expand at a CAGR of 3.3% from 2021 to 2027.

Test strips are a key component of urinalysis and blood glucose testing. These test strips are used to control or monitor glucose level of a diabetic, kidney disease and urinary tract infection (UTI) patient. Also, it helps diabetic or pre-diabetic people to track their blood glucose level on a regular basis without visiting a diagnostic laboratory or a clinic.

Get more details on this report - Request Free Sample PDF

Increasing prevalence of diabetes across the North America region will boost the market growth. For instance, according to the American Diabetes association (ADA) report, approximately 34.2 (10.5%) million Americans had diabetes in 2018. Among those cases, nearly 26.8 million people were diagnosed, and 7.3 million individuals were undiagnosed. . Furthermore, technological advancement in blood glucose strips for faster and accurate results will drive the market revenue.

Rising prevalence of other chronic diseases including urinary tract infections and related kidney disorders is another chief propelling factor for the market demand. Also, increasing incidence of kidney disorders owing to rising intake of alcohol will significantly drive market expansion. Moreover, lack of physical activities will lead to rise in prevalence of diabetes, augmenting market size. However, lack of reimbursement policies for test strips may hinder the industry growth.

North American Market, By Product

The diabetes test strips segment size was more than USD 5.1 billion in 2020. Growing geriatric population along with increasing prevalence of diabetes across the region will boost the market demand. Also, due to the ease in handling glucometers, patients are now preferring to use them for their personal use (home use). Furthermore, measuring blood glucose levels is essential to take or alter the medication, especially for insulin users. Thus, growing preference among the population for point of care testing is another major factor fostering the market revenue.

North American Market, By End-use

Home care setting segment accounted for USD 2.5 billion revenue in 2020 and is estimated to witness over of 3.6% growth between 2021 and 2027. Increasing number of retail pharmacies coupled with rising awareness among the population about several point of care testing methods will boost the segmental growth. Furthermore, increasing number of online portals commercialising test strips for personal use is another factor fostering the industry growth.

North American Market, By Country

U.S. test strips market revenue crossed USD 5.1 billion in 2020 and is set to observe a 3.4% growth rate till 2027. High pervasiveness of diabetes is due to adoption of sedentary lifestyle along with sub-optimal diet that will further drive the industry growth.

Also, rising prevalence of urinary tract infection in the country will boost the market revenue. For instance, according to the World Health Organization (WHO) report, in U.S., nearly 50% of women reported having a urinary tract infection at some point in their life. Thus, the rise in number of UTI will increase the product adoption, thereby supplementing the market demand. Furthermore, availability of advanced hospital infrastructure along with presence of major players will drive the market size.

Competitive Industry Landscape

  Major players operating in test strips industry are Abbott Laboratories, Roche Diabetes Care, Lifescan, B Braun, Siemens Healthineers, Arkray, Henry Schein and Tiadoc among others.

Companies undertake various strategies such as mergers, collaborations, new product launch, acquisitions, geographic expansions to strengthen their market share. For instance, in September 2020, Lifescan launched its OneTouch Amazon storefront for patients managing Type 1 and Type 2 diabetes.  The new web store includes the introduction of a OneTouch Verio 30-count test strip value-pack. This strategy is expected to enhance their service offering and increase its revenue growth.